Hepatitis Mice Cytotoxic T Lymphocyte Tolerance in Dendritic Cell Immunization Breaks

2 Hepatitis B virus (HBV) transgenic mice that are immunologically tolerant to HBV-encoded Ags represent a model of chronic HBV infection suitable for the development of therapeutic immunization strategies before testing in humans. Five lineages of HBV transgenic mice were immunized with plasmid DNA that encodes hepatitis B surface Ag (HBsAg) or with cytokine-activated bone marrow-derived dendritic cells (DCs) in an attempt to break tolerance to HBsAg at the B and T cell levels. DNA immunization stimulated an Ab response but not a cytotoxic T lymphocyte response to HBsAg in two of the five transgenic lineages studied. In contrast, infusion of activated transgenic or nontransgenic DCs stimulated a splenic CTL response in all three transgenic lineages immunized in this manner at precursor frequencies comparable to those in nontransgenic mice, indicating that DC function is normal, and HBsAg-specific CTLs are present but functionally silent in these transgenic animals. Importantly, none of the animals developed hepatitis or displayed suppressed viral gene expression or replication following either DNA immunization or DC administration even in the presence of anti-hepatitis B surface (HBs) Abs and HBs-specific CTLs. These results indicate that Ag presentation by cytokine-activated DCs can break tolerance and trigger an anti-viral CTL response in HBV transgenic mice, and they suggest that this strategy is more efficient than DNA immunization in this setting. Nonetheless, more efficient immunization strategies are needed to stimulate an immune response of sufficient quality and magnitude to achieve an immunotherapeutic antiviral effect. The Journal of Immunology, 1998, 161: 4520–4529.

[1]  A. Lanzavecchia,et al.  The duration of antigenic stimulation determines the fate of naive and effector T cells. , 1998, Immunity.

[2]  Antonio Lanzavecchia,et al.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.

[3]  J. Bluestone.  Is CTLA-4 a master switch for peripheral T cell tolerance? , 1997, Journal of immunology.

[4]  H. Davis,et al.  DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Reimann,et al.  MHC class I-restricted CTL responses to exogenous antigens. , 1996, Immunity.

[6]  R. Purcell,et al.  DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Antonio Lanzavecchia,et al.  T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.

[8]  Steinman Rm.  Dendritic cells and immune-based therapies. , 1996 .

[9]  S. Kurtzman,et al.  Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. , 1996, Cancer research.

[10]  F. Chisari,et al.  DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. , 1996, Journal of immunology.

[11]  A. Abbas,et al.  The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. , 1996, Immunity.

[12]  K. Inaba,et al.  Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity , 1996, The Journal of experimental medicine.

[13]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[14]  J. Mayordomo,et al.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.

[15]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[16]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.

[17]  S. Dillon,et al.  Detection of enhanced cytotoxic T lymphocyte response with spleenic dendritic cells enriched by a simple sequential adherence method. , 1996, Viral immunology.

[18]  T. Starzl,et al.  Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. , 1995, Transplantation.

[19]  R. Flavell,et al.  Coexpression of B7-1 and viral ("self") transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. , 1995, Immunity.

[20]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[21]  J. Reimann,et al.  DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. , 1995, Human gene therapy.

[22]  F. Chisari,et al.  Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice , 1995, Journal of virology.

[23]  Y. Barenholz,et al.  Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. , 1995, Journal of immunology.

[24]  F. Chisari,et al.  High-level hepatitis B virus replication in transgenic mice , 1995, Journal of virology.

[25]  D. Pardoll,et al.  Exposing the immunology of naked DNA vaccines. , 1995, Immunity.

[26]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.

[27]  E. Gilboa,et al.  Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[28]  M. Schleef,et al.  DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Chisari,et al.  Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. , 1995, Journal of immunology.

[30]  B. Moss,et al.  The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis , 1995, The Journal of experimental medicine.

[31]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[32]  J. Banchereau,et al.  Recent advances in the study of dendritic cells and follicular dendritic cells. , 1995, Immunology today.

[33]  F. Chisari,et al.  Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice , 1994, Journal of virology.

[34]  D. Harlan,et al.  Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  F. Chisari,et al.  Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways , 1994, Journal of virology.

[36]  F. Chisari,et al.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis , 1993, The Journal of experimental medicine.

[37]  A. Vitiello,et al.  HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. , 1993, Journal of immunology.

[38]  B. Rocha,et al.  Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen , 1993, The Journal of experimental medicine.

[39]  F. Chisari,et al.  HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon‐γ , 1992 .

[40]  F. Chisari,et al.  Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice , 1992, Journal of virology.

[41]  M. Moser,et al.  Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo , 1992, The Journal of experimental medicine.

[42]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[43]  R. Steinman,et al.  Dendritic cells pulsed with protein antigens in vitro can prime antigen- specific, MHC-restricted T cells in situ [published erratum appears in J Exp Med 1990 Oct 1;172(4):1275] , 1990, The Journal of experimental medicine.

[44]  R. Palmiter,et al.  Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. , 1990, Science.

[45]  R. Palmiter,et al.  Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice , 1989, Cell.

[46]  J. Sprent,et al.  T Cell Selection in the Thymus , 1988, Immunological reviews.

[47]  R. Palmiter,et al.  Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[49]  R. Palmiter,et al.  Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice , 1986, Journal of virology.

[50]  R. Palmiter,et al.  A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. , 1985, Science.

[51]  C. Taswell,et al.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. , 1981, Journal of immunology.